Brief: Grand Pharmaceutical Says Novasight Approved By NMPA For Commercialization In China
17/05/2023 12:49
May 17 (Reuters) - Grand Pharmaceutical 0512.HK :
* NOVASIGHT WAS APPROVED BY NMPA FOR COMMERCIALIZATION IN
CHINA
Further company coverage: 0512.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement